SAR-441169 is under clinical development by Lead Pharma and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAR-441169’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAR-441169 is under development for the treatment of autoimmune diseases including rheumatoid arthritis, psoriasis and inflammatory bowel disease. The drug candidate is administered by oral route. The program consists of drugs that act by targeting nuclear receptor retinoic acid receptor-related orphan receptor gamma (RORgamma).
Lead Pharma overview
Lead Pharma is a drug discovery company that develops, discovers, and commercializes innovative therapeutics against cancer and autoimmune diseases. The company offers products such as RORyT, ERRa, LXR, and New Target Development. Its lead product pipeline program RORyt regulates the production of pro-inflammatory protein and finds application in the therapeutic area of autoimmune diseases. The company also develops LXR. It has a collaboration with Sanofi. Lead Pharma is headquartered in Oss, the Netherlands.
For a complete picture of SAR-441169’s drug-specific PTSR and LoA scores, buy the report here.